EHA Congress

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors.

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims to shift induction therapy standards worldwide.

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML therapy and maintenance.

Ziftomenib plus 7+3 in newly diagnosed AML shows manageable safety and 90%+ deep responses with high MRD negativity and encouraging early survival in KOMET-007.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

Andrew Spencer, MBBS, discusses how the inMMyCar trial is finding promise for in vivo CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Susan Bal, MD, discusses outcomes with arlo-cel, a GPRC5D-targeted CAR T product in relapsed/refractory multiple myeloma.

A scale combining frailty, chronological age, and comorbidities showed distinct outcomes among patients who received allogeneic hematopoietic cell transplant.

At the European Hematology Association Congress, researchers presented on novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

Johannes Schetelig, MD, MSc, discusses the importance of preventing life-threatening infections in light of research showing high nonrelapse mortality with PTCy.

Johannes Schetelig, MD, MSc, discusses findings on graft-vs-host disease prophylaxis in unrelated donor allogeneic stem cell transplants.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

FBEM conditioning in ALL alloHSCT yields 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.

Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary disease.

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus venetoclax, according to recent analysis.

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.

Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating newly diagnosed multiple myeloma.

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved patient outcomes.

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk patients.

New trial results reveal BGB-16673's promising safety and efficacy in treating relapsed CLL/SLL, showing significant antitumor activity across diverse patient profiles.

New data reveals bexobrutideg shows promising efficacy and safety in treating relapsed/refractory chronic lymphocytic leukemia, offering hope for patients.

New findings reveal that combining erythropoiesis-stimulating agents with ruxolitinib maintains efficacy in treating myelofibrosis-related anemia.

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation due to adverse effects significantly.

The IRAKLIA study reveals that subcutaneous isatuximab offers comparable efficacy and improved patient satisfaction over intravenous administration for multiple myeloma.

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.